Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137812

Published: 2020

Journal Articles

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD, Cory Mavis, MSc, Juan J Gu, PhD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143237

Published: 2020

Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142859

Published: 2020

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

Blood (2019) 134 (Supplement_1): 1554.

https://doi.org/10.1182/blood-2019-129199

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era

Suchitra Sundaram, MD, Matthew Gravina, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Pallawi Torka, MD

Blood (2019) 134 (Supplement_1): 4039.

https://doi.org/10.1182/blood-2019-130382

Published: 2019

Journal Articles

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Suchitra Sundaram, MD, Matthew Gravina, MD, Pallawi Torka, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 4058.

https://doi.org/10.1182/blood-2019-132244

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Tara Daly, BS, Thomas Ippolito, MSc, Juan J. Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2019) 134 (Supplement_1): 5303.

https://doi.org/10.1182/blood-2019-129052

Published: 2019

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

Novel mRNA Detection Assay for Quantifying CD30 Expression in Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Jerry Thwin Wong, MD PhD, Thomas Ippolito, MSc, Andrea Schlosser, Francisco J. Hernandez-Ilizaliturri, MD, Vishala T. Neppalli, MD

Blood (2018) 132 (Supplement 1): 5311.

https://doi.org/10.1182/blood-2018-99-120238

Published: 2018

Journal Articles

Outcomes of Follicular Lymphoma (FL) with Early Progression (EP): Does Choice of Second Line Therapy Impact the Course of Disease?

Ahmad Hanif, MD, Sumera Khan, MSc, MD, Pallawi Torka, MD, Kris Attwood, PhD MS, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2018-99-117908

Published: 2018

Journal Articles

Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Blood (2018) 132 (Supplement 1): 451.

https://doi.org/10.1182/blood-2018-99-111530

Published: 2018

Journal Articles

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

Juan Gu, MD PhD, Dennis C Gaughan, Simran Gill, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2018-99-110282

Published: 2018

Journal Articles

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Juan Gu, MD PhD, Lianjuan Yang, MD PhD, Dennis C Gaughan, Ling He, MD PhD, Weina Shen, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5378.

https://doi.org/10.1182/blood-2018-99-113997

Published: 2018

Journal Articles

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Sumera Khan, MSc, MD, Kyle Runckel, BS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2018-99-118480

Published: 2018

Journal Articles

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Zuguang Xia, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Ye Guo, Xiaonan Hong, Junning Cao, MD

Blood (2018) 132 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2018-99-118872

Published: 2018

Journal Articles

Dose Reductions in Ibrutinib Therapy Are Not Associated with Inferior Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL)

Othman S. Akhtar, MD, Kris Attwood, PhD MS, Ian Lund, PA-C, Ryan Hare, PharmD, Francisco J. Hernandez-Ilizaliturri, MD, Pallawi Torka, MD

Blood (2018) 132 (Supplement 1): 5567.

https://doi.org/10.1182/blood-2018-99-112334

Published: 2018

NARROW

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Novel mRNA Detection Assay for Quantifying CD30 Expression in Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Outcomes of Follicular Lymphoma (FL) with Early Progression (EP): Does Choice of Second Line Therapy Impact the Course of Disease?

Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Dose Reductions in Ibrutinib Therapy Are Not Associated with Inferior Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only